| 张鹏 蒋兰兰 许向红 罗勇 袁璐 马建华.吡格列酮治疗对2 型糖尿病合并代谢综合征患者血糖、胰岛素抵抗和炎症因子的影响[J].,2016,16(17):3338-3341 |
| 吡格列酮治疗对2 型糖尿病合并代谢综合征患者血糖、胰岛素抵抗和炎症因子的影响 |
| The Influence of Blood Sugar, Insulin Resistance and InflammatoryCytokines on Type 2 Diabetes Patients with Metabolic Syndrome Treated byPioglitazone |
| |
| DOI： |
| 中文关键词: 吡格列酮 2 型糖尿病 代谢综合征 血糖 胰岛素抵抗 炎症因子 |
| 英文关键词: Pioglitazone Type 2 diabetes Metabolic syndrome Blood sugar Insulin resistance Inflammatory cytokines |
| 基金项目: |
|
| 摘要点击次数: 745 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨吡格列酮治疗对2 型糖尿病合并代谢综合征患者血糖、胰岛素抵抗和炎症因子的影响。方法：回顾性分析我院
2013 年8 月-2015 年2月收治的96 例2型糖尿病合并代谢综合征患者病例资料，根据治疗方法的不同分为观察组和对照组，每
组48 例，两组患者均给予糖尿病常规基础治疗，在此基础上，观察组患者给予吡格列酮治疗，治疗3 个月。检测治疗前后血糖指
标包括空腹血糖（FPG）、餐后2 小时血糖（2hPG）以及糖化血糖蛋白（HbA1c），胰岛素抵抗指标包括空腹胰岛素（FINS）和胰岛素
抵抗指数（HOMA-IR）和炎症因子包括超敏C 反应蛋白（hs-CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-alpha（TNF-alpha）。结果：观察组
治疗后FPG、2 hPG、HbA1c 分别为（6.19± 2.24）mmol/L、（8.30± 2.48）mmol/L 和（6.01± 1.23）%，均显著低于治疗前和对照组治疗
后，差异有统计学意义（P＜0.05）；观察组治疗后FINS 和HOMA-IR 分别为（6.60± 1.92）mIU/L 和2.08± 1.00，均较治疗前和对照
组治疗后显著降低，差异有统计学意义（P＜0.05）；观察组治疗后hs-CRP、IL-6 和TNF-alpha分别为（6.12± 1.67）ng/L、（62.65± 10.30）
ng/L 和（83.16± 16.55）ng/L，均较治疗前和对照组治疗后显著降低，差异有统计学意义（P＜0.05）。结论：吡格列酮治疗可以显著降
低2 型糖尿病合并代谢综合征患者血糖水平，改善胰岛素抵抗，降低炎症反应，值得进一步研究。 |
| 英文摘要: |
| Objective:To explore the influence of blood sugar, insulin resistance and inflammatory cytokines on type 2 diabetes
patients with metabolic syndrome treated by Pioglitazon.Methods:96 cases type 2 diabetes patients with metabolic syndrome were divided
into observation group and control group according to therapeutic method, 48 cases in each group, patients in two groups were given
diabetes treatment on a regular basis, and on this basis, the observation group was treated with pioglitazone, treated for 3 months. Detected
blood sugar index including fasting plasma glucose (FPG), blood sugar 2 hours after meal (2hPG) and glycosylated protein (HbA1c),
blood sugar insulin resistance index including fasting insulin (FINS) and insulin resistance index (HOMA-IR) and inflammation factors
including hypersensitive c-reactive protein (hs-CRP) and interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) before and after
treatment.Results:The levels of FPG, 2hPG, HbA1c in observation group after treatment were respectively （6.19 ± 2.24）mmol/L,
（8.30± 2.48）mmol/Land（6.01± 1.23）%, they were significantly lower than before treatment and the control group after treatment, the
difference was statistically significant (P<0.05); The levels of FINS and HOMA-IR in observation group after treatment were respectively
（6.60± 1.92）mIU/L and 2.08± 1.00, they were significantly decreased than before treatment and the control group after treatment, the
difference was statistically significant (P<0.05); The levels of hs-CRP, IL-6 and TNF-alpha in observation group after treatment were respectively（
6.12± 1.67）ng/L,（62.65± 10.30）ng/Land（83.16± 16.55）ng/L, they were significantly decreased than before treatment and the
control group after treatment, the difference was statistically significant (P<0.05).Conclusion:Pioglitazone can significantly reduce blood
sugar levels and improve insulin resistance, reduce inflammation in type 2 diabetes patients with metabolic syndrome, it deserves further
research. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
